Skip to content

Study · In vitro (cells) · 2015

7 results

MGF enhances tenocyte invasion through MMP-2 activity via the FAK-ERK1/2 pathway.

Zhang B, Luo Q, Sun J, Xu B, Ju Y, Yang L, Song G

Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society1 May 2015Cited by 8 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In a transwell system, MGF-C25E significantly promoted tenocyte invasion.

    In plain wordsIn cells, the MGF-C25E peptide made tendon cells invade more.

    Outcome
    IncreaseTenocyte invasion
    Study

    n: not reported in source

    tenocyte invasion in a transwell system
    Outcome group
    Tendon and ligament healing · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In this study, using a transwell system, we found that MGF-C25E (a synthetic mechano-growth factor E peptide) significantly promotes tenocyte invasion, which was accompanied by the increased phosphorylation of focal adhesion kinase (FAK) and extracellular signal regulated kinase1/2 (ERK1/2) as well…
  2. 02LabIn vitro (cells)Mechanism

    In tenocytes, MGF-C25E increased the phosphorylation of focal adhesion kinase (FAK).

    In plain wordsIn cells, MGF-C25E raised the activation of a signalling protein called FAK.

    Outcome
    IncreaseFAK phosphorylation
    Study

    n: not reported in source

    tenocyte invasion in a transwell system
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In this study, using a transwell system, we found that MGF-C25E (a synthetic mechano-growth factor E peptide) significantly promotes tenocyte invasion
    1 context sentence
    Summary · context
    the increased phosphorylation of focal adhesion kinase (FAK) and extracellular signal regulated kinase1/2 (ERK1/2)
  3. 03LabIn vitro (cells)Mechanism

    In tenocytes, MGF-C25E increased the phosphorylation of extracellular signal regulated kinase1/2 (ERK1/2).

    In plain wordsIn cells, MGF-C25E raised the activation of a signalling protein called ERK1/2.

    Outcome
    IncreaseERK1/2 phosphorylation
    Study

    n: not reported in source

    tenocyte invasion in a transwell system
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    the increased phosphorylation of focal adhesion kinase (FAK) and extracellular signal regulated kinase1/2 (ERK1/2)
  4. 04LabIn vitro (cells)Mechanism

    In tenocytes, MGF-C25E increased the activity of matrix metalloproteinase-2 (MMP-2).

    In plain wordsIn cells, MGF-C25E raised the activity of the enzyme MMP-2.

    Outcome
    IncreaseMMP-2 activity
    Study

    n: not reported in source

    tenocyte invasion in a transwell system
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    as well as the increased activity of matrix metalloproteinases-2 (MMP-2).

Studies that did not test the peptide alone3

In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking MGF / PEG-MGF.

  1. 05LabNot a test of MGF / PEG-MGF aloneIn vitro (cells)Mechanism

    In tenocytes, the MMP-2 inhibitor OA-Hy blocked tenocyte invasion promoted by MGF-C25E.

    In plain wordsIn cells, an MMP-2 blocker stopped the extra tendon cell invasion that MGF-C25E caused.

    Outcome
    DecreaseMGF-C25E-promoted invasion after MMP-2 inhibition (OA-Hy)
    Study

    n: not reported in source

    tenocyte invasion in a transwell system
    Outcome group
    Receptor activity and mechanism · Musculoskeletal

    Source sentences

    Summary
    The MMP-2 inhibitor OA-Hy blocked MGF-C25E-promoted tenocyte invasion.

    In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MGF / PEG-MGF.

  2. 06LabNot a test of MGF / PEG-MGF aloneIn vitro (cells)Mechanism

    In tenocytes, inhibitors of FAK or ERK1/2 blocked tenocyte invasion promoted by MGF-C25E.

    In plain wordsIn cells, blockers of FAK or ERK1/2 stopped the extra tendon cell invasion that MGF-C25E caused.

    Outcome
    DecreaseMGF-C25E-promoted invasion after FAK or ERK1/2 inhibition
    Study

    n: not reported in source

    tenocyte invasion in a transwell system
    Outcome group
    Receptor activity and mechanism · Musculoskeletal

    Source sentences

    Summary
    Inhibitors of FAK or ERK1/2 blocked MGF-C25E-promoted tenocyte invasion and MMP-2 activity as well.

    In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MGF / PEG-MGF.

  3. 07LabNot a test of MGF / PEG-MGF aloneIn vitro (cells)Mechanism

    In tenocytes, inhibitors of FAK or ERK1/2 blocked the MMP-2 activity promoted by MGF-C25E.

    In plain wordsIn cells, blockers of FAK or ERK1/2 stopped the extra MMP-2 activity that MGF-C25E caused.

    Outcome
    DecreaseMGF-C25E-promoted MMP-2 activity after FAK or ERK1/2 inhibition
    Study

    n: not reported in source

    tenocyte invasion in a transwell system
    Outcome group
    Receptor activity and mechanism · Musculoskeletal

    Source sentences

    Summary
    Inhibitors of FAK or ERK1/2 blocked MGF-C25E-promoted tenocyte invasion and MMP-2 activity as well.

    In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MGF / PEG-MGF.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.